Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Avastin Approval For Breast Cancer, Will More Patients Hit Price Cap?

Executive Summary

FDA approval of Genentech's Avastin for first-line treatment of metastatic breast cancer may trigger the first significant trial of the biotech's Avastin patient assistance program, which caps annual drug expenditures at $55,000 for approved indications but has not seen much utilization by colorectal or non-small cell lung cancer patients
Advertisement

Related Content

Genentech May Not Get A Chance To Appeal FDA's Decision To Withdraw Avastin's Breast Cancer Approval
Genentech May Not Get A Chance To Appeal FDA's Decision To Withdraw Avastin's Breast Cancer Approval
AVADO Presented At ASCO; But After The Fanfare, What Does It Signify?
AVADO Presented At ASCO; But After The Fanfare, What Does It Signify?
Next For Genentech: Tackling Neuroscience And Infectious Disease
Analysis Of Recent Drug Reviews Illuminates Path For Future NDAs
Avastin Growth Not Limited To Breast Cancer In 2008, Genentech Says
Avastin Growth Not Limited To Breast Cancer In 2008, Genentech Says
Progression-Free Survival Represents Clinical Benefit, But How Much? – ODAC
ODAC Split On Avastin Use In First-Line Metastatic Breast Cancer
Advertisement
UsernamePublicRestriction

Register

PS049371

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel